Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
KERX's Cash to Debt is ranked higher than
90% of the 773 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.62 vs. KERX: No Debt )
KERX' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.90
KERX's Equity to Asset is ranked higher than
94% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. KERX: 0.90 )
KERX' s 10-Year Equity to Asset Range
Min: -0.06   Max: 0.93
Current: 0.9

-0.06
0.93
Interest Coverage No Debt
KERX's Interest Coverage is ranked higher than
73% of the 433 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 124.75 vs. KERX: No Debt )
KERX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: 46.05
M-Score: -2.81
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -672.61
KERX's Operating margin (%) is ranked lower than
56% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.93 vs. KERX: -672.61 )
KERX' s 10-Year Operating margin (%) Range
Min: -15010.67   Max: 38.97
Current: -672.61

-15010.67
38.97
Net-margin (%) -667.60
KERX's Net-margin (%) is ranked lower than
57% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.07 vs. KERX: -667.60 )
KERX' s 10-Year Net-margin (%) Range
Min: -13813.48   Max: 41.62
Current: -667.6

-13813.48
41.62
ROE (%) -102.93
KERX's ROE (%) is ranked lower than
55% of the 727 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. KERX: -102.93 )
KERX' s 10-Year ROE (%) Range
Min: -216.51   Max: 32.67
Current: -102.93

-216.51
32.67
ROA (%) -76.90
KERX's ROA (%) is ranked lower than
56% of the 748 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. KERX: -76.90 )
KERX' s 10-Year ROA (%) Range
Min: -409.52   Max: 25.69
Current: -76.9

-409.52
25.69
ROC (Joel Greenblatt) (%) -13490.83
KERX's ROC (Joel Greenblatt) (%) is ranked lower than
57% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.91 vs. KERX: -13490.83 )
KERX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -48355.36   Max: 10444.68
Current: -13490.83

-48355.36
10444.68
EBITDA Growth (%) 17.20
KERX's EBITDA Growth (%) is ranked higher than
81% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. KERX: 17.20 )
KERX' s 10-Year EBITDA Growth (%) Range
Min: -45.1   Max: 71.3
Current: 17.2

-45.1
71.3
EPS Growth (%) 18.30
KERX's EPS Growth (%) is ranked higher than
81% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. KERX: 18.30 )
KERX' s 10-Year EPS Growth (%) Range
Min: -44.5   Max: 60
Current: 18.3

-44.5
60
» KERX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

KERX Guru Trades in Q1 2013

Paul Tudor Jones Sold Out
» More
Q3 2013

KERX Guru Trades in Q3 2013

Jim Simons 991,100 sh (New)
» More
Q4 2013

KERX Guru Trades in Q4 2013

Jim Simons Sold Out
» More
Q1 2014

KERX Guru Trades in Q1 2014

Pioneer Investments 284,299 sh (New)
Steven Cohen 1,525,058 sh (New)
Jim Simons 18,700 sh (New)
Seth Klarman 6,310,850 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with KERX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Seth Klarman 2014-03-31 New Buy2.6%$12.16 - $16.88 $ 15.393%6310850
John Burbank 2012-12-31 Sold Out 0.06%$2.31 - $3.14 $ 15.39466%0
John Burbank 2012-09-30 New Buy0.06%$1.79 - $2.83 $ 15.39640%500000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.80
KERX's P/B is ranked higher than
50% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.22 vs. KERX: 9.80 )
KERX' s 10-Year P/B Range
Min: 0.46   Max: 49
Current: 9.8

0.46
49
P/S 129.00
KERX's P/S is ranked lower than
54% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. KERX: 129.00 )
KERX' s 10-Year P/S Range
Min: 1.1   Max: 1911
Current: 129

1.1
1911
EV-to-EBIT -20.74
KERX's EV-to-EBIT is ranked lower than
51% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.81 vs. KERX: -20.74 )
KERX' s 10-Year EV-to-EBIT Range
Min: 2.8   Max: 22.2
Current: -20.74

2.8
22.2
Current Ratio 9.55
KERX's Current Ratio is ranked higher than
94% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. KERX: 9.55 )
KERX' s 10-Year Current Ratio Range
Min: 1.88   Max: 106.93
Current: 9.55

1.88
106.93
Quick Ratio 9.55
KERX's Quick Ratio is ranked higher than
95% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. KERX: 9.55 )
KERX' s 10-Year Quick Ratio Range
Min: 1.88   Max: 106.93
Current: 9.55

1.88
106.93

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.10
KERX's Price/Net Cash is ranked higher than
91% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. KERX: 10.10 )
KERX' s 10-Year Price/Net Cash Range
Min: 1.09   Max: 29.11
Current: 10.1

1.09
29.11
Price/Net Current Asset Value 10.10
KERX's Price/Net Current Asset Value is ranked higher than
87% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. KERX: 10.10 )
KERX' s 10-Year Price/Net Current Asset Value Range
Min: 1.07   Max: 29.11
Current: 10.1

1.07
29.11
Price/Tangible Book 10.00
KERX's Price/Tangible Book is ranked higher than
56% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. KERX: 10.00 )
KERX' s 10-Year Price/Tangible Book Range
Min: 0.93   Max: 26.2
Current: 10

0.93
26.2
Price/Median PS Value 1.70
KERX's Price/Median PS Value is ranked higher than
59% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. KERX: 1.70 )
KERX' s 10-Year Price/Median PS Value Range
Min: 0.02   Max: 26.92
Current: 1.7

0.02
26.92
Forward Rate of Return (Yacktman) -1.57
KERX's Forward Rate of Return (Yacktman) is ranked higher than
64% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. KERX: -1.57 )
KERX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -121.4   Max: -17
Current: -1.57

-121.4
-17

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:KYX.Germany
Keryx Biopharmaceuticals, Inc is a Delaware corporation incorporated in Delaware in October 1998. The Company is a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. The company is developing ZerenexTM (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes. Zerenex is also in Phase 2 development in the U.S. for the management of phosphorus and iron deficiency in anemic patients with Stages 3 to 5 non-dialysis dependent CKD. It is also engage in business development activities that include seeking strategic relationships for Zerenex, as well as evaluating compounds and companies for in-licensing or acquisition. Its only drug candidate is Zerenex. It may engage in business development activities that include seeking strategic relationships for Zerenex, as well as evaluating compounds and companies for in-licensing or acquisition. Its competitors include pharmaceutical companies and biotechnology companies, as well as universities and public and private research institutions.
» More Articles for KERX

Headlines

Articles On GuruFocus.com
Seth Klarman Tops Guru Scoreboard for First Half 2014 Jul 05 2014 
Baupost’s Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals May 12 2014 
Weekly Insider Sells Highlight: KERX, ORCL, QCOM, GILD Mar 24 2014 
Weekly Insider Sells Highlight: FLT, KERX, KOG, MEI, HTZ Jan 06 2014 
comment on KERX Mar 02 2013 
Can Keryx Succeed Without Partnership? Apr 24 2012 
Keryx Still Has High Potential from Zerenex Apr 12 2012 
Bio drug Nov 03 2011 
comment on KERX Oct 26 2011 
Keryx Biopharmaceuticals Inc. (KERX) CFO James F Iii Oliviero sells 14,064 Shares Jan 03 2011 


More From Other Websites
Zerenex(TM) (Ferric Citrate) Long-Term Phase 3 Study Results Published in the Journal of the... Jul 24 2014
Keryx drug improves phosphorus, iron in kidney patients -trial Jul 24 2014
Zerenex(TM) (Ferric Citrate) Long-Term Phase 3 Study Results Published in the Journal of the... Jul 24 2014
Keryx Biopharmaceuticals, Inc. to Present at the 9th Annual JMP Securities Healthcare Conference Jul 17 2014
Keryx Biopharmaceuticals Announces Issuance of Two U.S. Patents for Zerenex(TM) Covering Orally... Jul 17 2014
KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 24 2014
Keryx Biopharmaceuticals: Baupost Group's New Position Suggests A Possible Takeout And 100%+ Gains Jun 24 2014
Keryx Biopharmaceuticals Announces Issuance of Two U.S. Patents for Zerenex(TM) Covering Orally... Jun 18 2014
Keryx Biopharmaceuticals, Inc. to Present at the 9th Annual JMP Securities Healthcare Conference Jun 17 2014
The Baupost Group buys a new position in Keryx Biopharmaceuticals Jun 06 2014
Must-know highlights of the Baupost Group’s 1Q 2014 positions Jun 05 2014
Keryx Biopharmaceuticals, Inc. to Present at the 35th Annual Goldman Sachs Global Healthcare... Jun 05 2014
Keryx Biopharma: Approval Delay Does Not Change Zerenex Prospects Or Differentiation May 29 2014
Options with decreasing implied volatility May 23 2014
Keryx PDUFA extension creates buying opportunity, says Oppenheimer May 23 2014
KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 22 2014
Keryx announces FDA extends PDUFA date for Zerenex May 22 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide